Statement of Ownership (sc 13g)
26 Juillet 2013 - 4:23PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
(Rule 13d-102)
Information Statement Pursuant to Rules 13d-1 and 13d-2
Under the
Securities Exchange Act of 1934
(Amendment No. )*
|
Portola Pharmaceuticals, Inc.
|
(Name of Issuer)
|
Common Stock, $0.001 Par Value Per Share
|
(Title of Class of Securities)
(CUSIP Number)
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this schedule is filed:
¨
Rule 13d-1(b)
x
Rule 13d-1(c)
¨
Rule 13d-1(d)
*
|
|
The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
|
The information
required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but
shall be subject to all other provisions of the Act (however, see the Notes).
|
|
|
|
|
|
|
CUSIP No. N/A
|
1.
|
|
NAME OF REPORTING
PERSON
Brookside Capital Partners Fund, L.P.
|
2.
|
|
CHECK THE APPROPRIATE BOX IF A
MEMBER OF A GROUP*
(a)
¨
(b)
¨
|
3.
|
|
SEC USE ONLY
|
4.
|
|
CITIZENSHIP OR PLACE OF
ORGANIZATION
Delaware
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
|
5.
|
|
SOLE VOTING POWER
1,785,013 shares
|
|
6.
|
|
SHARED VOTING POWER
0
|
|
7.
|
|
SOLE DISPOSITIVE POWER
1,785,013 shares
|
|
8.
|
|
SHARED DISPOSITIVE POWER
0
|
9.
|
|
AGGREGATE AMOUNT BENEFICIALLY
OWNED BY EACH REPORTING PERSON
1,785,013
shares
|
10.
|
|
CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES
¨
|
11.
|
|
PERCENT OF CLASS REPRESENTED BY
AMOUNT IN ROW (9)
5.27%
|
12.
|
|
TYPE OF REPORTING
PERSON
PN
|
|
|
|
|
|
|
|
CUSIP No. N/A
|
13.
|
|
NAME OF REPORTING
PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Brookside Capital Trading Fund, L.P.
|
14.
|
|
CHECK THE APPROPRIATE BOX IF A
MEMBER OF A GROUP*
(a)
¨
(b)
¨
|
15.
|
|
SEC USE ONLY
|
16.
|
|
CITIZENSHIP OR PLACE OF
ORGANIZATION
Delaware
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
|
17.
|
|
SOLE VOTING POWER
400,000 shares
|
|
18.
|
|
SHARED VOTING POWER
0
|
|
19.
|
|
SOLE DISPOSITIVE POWER
400,000 shares
|
|
20.
|
|
SHARED DISPOSITIVE POWER
0
|
21.
|
|
AGGREGATE AMOUNT BENEFICIALLY
OWNED BY EACH REPORTING PERSON
400,000
Shares
|
22.
|
|
CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES
¨
|
23.
|
|
PERCENT OF CLASS REPRESENTED BY
AMOUNT IN ROW (9)
1.18%
|
24.
|
|
TYPE OF REPORTING
PERSON
PN
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Item 1
|
|
(a).
|
|
Name of Issuer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The name of the issuer to which this filing on Schedule 13G relates is Portola Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
|
|
Item 1
|
|
(b).
|
|
Address of Issuers Principal Executive Offices
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The principal executive offices of the Company are located at 270 E. Grand Avenue, San Francisco, CA 94080.
|
|
|
|
|
|
|
|
|
|
Item 2
|
|
(a).
|
|
Name of Person Filing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
This Statement is being filed on behalf of the following (collectively, the Reporting
Persons): (1) Brookside Capital Partners Fund, L.P., a Delaware limited partnership (Partners Fund). Brookside Capital Investors, L.P., a Delaware limited partnership (Brookside Investors) is the sole general partner of
the Brookside Fund. Brookside Capital Management, LLC, a Delaware limited liability company (Brookside Management), is the sole general partner of Brookside Investors. (2) Brookside Capital Trading Fund, L.P., a Delaware limited
partnership (Trading Fund). Brookside Capital Investors II, L.P., a Delaware limited partnership (Brookside Investors II) is the sole general partner of the Trading Fund. Brookside Management is the sole general partner of
Brookside Investors.
The Reporting Persons have entered into a Joint
Filing Agreement, dated July 26, 2013, a copy of which is filed with this Schedule 13G as
Exhibit A
, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1)
under the Securities Exchange Act of 1934.
|
|
|
|
|
|
|
|
|
|
Item 2
|
|
(b).
|
|
Address of Principal Business Office or, if none, Residence
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The principal business address of each of the Partners Fund, Trading Fund, Brookside Investors, Brookside Investors II, and Brookside
Management is c/o John Hancock Tower, 200 Clarendon Street, Boston, MA 02116.
|
|
|
|
|
|
|
|
|
|
Item 2
|
|
(c).
|
|
Citizenship
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Each of Partners Fund, Trading Fund, Brookside Investors, Brookside Investors II, and Brookside Management is organized under the laws
of the State of Delaware.
|
|
|
|
|
|
|
|
|
|
Item 2
|
|
(d).
|
|
Title of Class of Securities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The class of equity securities of the Company to which this filing on Schedule 13G/A relates is Common Stock, $0.001 Par Value Per
Share.
|
|
|
|
|
|
|
|
|
|
Item 2
|
|
(e).
|
|
CUSIP Number
|
|
|
|
|
|
|
|
|
|
|
|
|
|
737010108
|
|
|
|
|
|
|
|
Item 3.
|
|
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
Not applicable.
|
|
|
|
|
|
|
|
|
(a)
|
|
¨
|
|
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
|
|
|
|
|
|
|
(b)
|
|
¨
|
|
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 73c).
|
|
|
|
|
|
|
(c)
|
|
¨
|
|
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
|
|
|
|
|
|
|
(d)
|
|
¨
|
|
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
|
|
|
|
|
|
|
(e)
|
|
¨
|
|
An investment adviser in accordance with §13d-1(b)(1)(ii)(E).
|
|
|
|
|
|
|
(f)
|
|
¨
|
|
An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
|
|
|
|
|
|
|
(g)
|
|
¨
|
|
A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
|
|
|
|
|
|
|
(h)
|
|
¨
|
|
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
|
|
|
|
|
|
|
(i)
|
|
¨
|
|
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C.
80a-3).
|
|
|
|
|
|
|
(j)
|
|
¨
|
|
Group, in accordance with §240.13d-1(b)(1)(ii)(J).
|
|
|
|
|
|
|
|
|
x
|
|
If this statement is filed pursuant to §240.13d-1(c), check this box
.
|
|
|
|
|
|
|
|
|
|
|
|
Item 4.
|
|
Ownership
|
|
|
|
|
|
|
|
|
|
Item 4.
|
|
(a).
|
|
Amount beneficially owned
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of the close of business on May 23, 2013, the Reporting Persons beneficially owned 2,185,013 Ordinary Shares. Partners Fund acts by
and through its general partner, Brookside Investors. Trading Fund acts by and through its general partner, Brookside Investors II. Brookside Investors acts by and through its general partner, Brookside Management. Brookside Investors II acts by and
through its general partner, Brookside Management.
|
|
|
|
|
|
|
|
|
|
Item 4.
|
|
(b).
|
|
Percent of Class
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of the close of business on May 23, 2013, the Reporting Persons beneficially owned 6.45% of the Ordinary Shares of the Company. The
aggregate percentage of Common Stock reported owned by the Reporting Persons is based upon 33,882,938 Ordinary Shares outstanding, which is the total number of shares of Ordinary Shares outstanding as of March 31, 2013, based on representations made
in the Companys Form 424B4 filed May 22, 2013 with the Securities and Exchange Commission.
|
|
|
|
|
|
|
|
|
|
Item 4.
|
|
(c).
|
|
Number of shares as to which such person has
:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(i)
|
|
sole power to vote or to direct the vote: 2,185,013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(ii)
|
|
shared power to vote or to direct the vote: 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(iii)
|
|
sole power to dispose or to direct the disposition of: 2,185,013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(iv)
|
|
shared power to dispose or to direct the disposition of: 0
|
|
|
|
|
|
|
|
Item 5.
|
|
Ownership of Five Percent or Less of a Class
|
|
|
|
|
|
|
|
If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial
owners of more than five percent of the Ordinary Shares check the following:
|
|
.
|
|
|
|
|
Item 6.
|
|
Ownership of More than Five Percent on Behalf of Another Person
|
|
|
|
|
|
|
|
|
|
|
Not Applicable.
|
|
|
|
|
|
|
Item 7.
|
|
Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company:
|
|
|
|
|
Not Applicable.
|
|
|
|
|
Item 8.
|
|
Identification and Classification of Members of the Group
|
|
|
|
|
|
|
|
|
|
|
Not Applicable.
|
|
|
|
|
|
|
|
|
Item 9.
|
|
Notice of Dissolution of Group
|
|
|
|
|
|
|
|
|
|
|
Not Applicable.
|
|
|
|
|
|
|
|
|
Item 10.
|
|
Certification
|
|
|
|
|
|
|
|
|
|
|
By signing below, the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not
acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that
purpose or effect.
|
|
|
|
|
Dated: July 26, 2013
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete, and correct.
|
|
|
BROOKSIDE CAPITAL PARTNERS FUND, L.P.
|
|
|
By:
|
|
/s/ William E. Pappendick IV
|
|
|
Name: William E. Pappendick IV
|
|
|
Title: Managing Director
|
|
BROOKSIDE CAPITAL TRADING FUND, L.P.
|
|
|
By:
|
|
/s/ William E. Pappendick IV
|
|
|
Name: William E. Pappendick IV
|
|
|
Title: Managing Director
|
Exhibit A
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G
The undersigned hereby agree as follows:
|
(1)
|
Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf of each of them; and
|
|
(2)
|
Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of such information concerning
such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making this filing, unless such person knows or has reason to believe that such information is
inaccurate.
|
Dated: July 26, 2013
|
|
|
BROOKSIDE CAPITAL PARTNERS FUND, L.P.
|
|
|
By:
|
|
/s/ William E. Pappendick IV
|
|
|
Name: William E. Pappendick IV
|
|
|
Title: Managing Director
|
|
BROOKSIDE CAPITAL TRADING FUND, L.P.
|
|
|
By:
|
|
/s/ William E. Pappendick IV
|
|
|
Name: William E. Pappendick IV
|
|
|
Title: Managing Director
|
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Portola Pharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur Portola Pharmaceuticals Inc